A detailed history of Private Management Group Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Private Management Group Inc holds 2,916 shares of ABBV stock, worth $496,740. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,916
Previous 2,738 6.5%
Holding current value
$496,740
Previous $469,000 22.6%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$163.84 - $199.33 $29,163 - $35,480
178 Added 6.5%
2,916 $575,000
Q1 2024

May 08, 2024

SELL
$159.82 - $182.1 $11,986 - $13,657
-75 Reduced 2.67%
2,738 $498,000
Q4 2023

Feb 01, 2024

SELL
$137.6 - $154.97 $26,556 - $29,909
-193 Reduced 6.42%
2,813 $435,000
Q2 2023

Aug 07, 2023

BUY
$132.51 - $164.9 $39,620 - $49,305
299 Added 11.05%
3,006 $404,000
Q1 2023

May 08, 2023

BUY
$144.61 - $166.54 $5,495 - $6,328
38 Added 1.42%
2,707 $431,000
Q4 2022

Feb 02, 2023

BUY
$138.31 - $165.87 $48,685 - $58,386
352 Added 15.19%
2,669 $431,000
Q3 2022

Feb 06, 2023

SELL
$134.21 - $153.93 $47,241 - $54,183
-352 Reduced 13.19%
2,317 $311,000
Q3 2022

Feb 06, 2023

SELL
$134.21 - $153.93 $47,241 - $54,183
-352 Reduced 13.19%
2,317 $310,000
Q2 2022

Aug 05, 2022

BUY
$137.62 - $174.96 $4,128 - $5,248
30 Added 1.31%
2,317 $355,000
Q1 2022

May 06, 2022

SELL
$131.98 - $163.75 $7,918 - $9,825
-60 Reduced 2.56%
2,287 $371,000
Q4 2021

Feb 08, 2022

BUY
$107.43 - $135.93 $39,749 - $50,294
370 Added 18.72%
2,347 $318,000
Q3 2021

Nov 09, 2021

BUY
$106.4 - $120.78 $210,352 - $238,782
1,977 New
1,977 $213,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Private Management Group Inc Portfolio

Follow Private Management Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Management Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Private Management Group Inc with notifications on news.